PACB Stock Analysis: Buy, Sell, or Hold?
PACB - Pacific Biosciences of California, Inc.
$1.30
0.03 (2.36%)
â˛
5d:
+0.0%
30d:
+17.12%
90d:
-3.7%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When PACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PACB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PACB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PACB is currently trading at $1.30, which is considered fair relative to its 30-day fair value range of $1.17 to $1.42.
Technical Outlook: Technically, PACB is in a uptrend. Immediate support is located at $1.25, while resistance sits at $1.54.
Market Sentiment: PACB scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.16 (+65.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PACB is in a uptrend. Immediate support is located at $1.25, while resistance sits at $1.54.
Market Sentiment: PACB scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.16 (+65.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.17 -
$1.42
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding PACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 65.9% below Wall St target ($2.16)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.17 -
$1.42
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.25
Resistance Level
$1.55
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.23
Wall Street Target
$2.16
(+65.9%)
Revenue Growth (YoY)
-1.9%
Profit Margin
-82.5%
Share & Embed Analysis
Last updated: September 13, 2026 1:24 AM ET
Data refreshes hourly during market hours. Next update: 2:24 AM
Data refreshes hourly during market hours. Next update: 2:24 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
Advanced PACB Option Strategies
Professional options setups generated by AI based on today's PACB price and gamma walls.
